AstraZeneca Pharma logo

AstraZeneca Pharma

ASTRAZEN NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹15,285 Cr
Volatility
Low Risk
P/E Ratio
88.89
EBITDA
₹291 Cr
Return on Equity
21.49%
Debt to Equity
0.13
Book Value
₹349.12
EPS
₹52.4
52W High
₹9,849.5
52W Low
₹6,120.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 51.4%

Weaknesses

1
  • Stock is trading at 17.3 times its book value

Growth Rate

Revenue Growth
31.15% higher than 3Y
Net Income Growth
62.06% higher than 3Y
Cash Flow Change
-123% higher than 3Y
ROE
43.08% higher than 3Y
ROCE
31.61% higher than 3Y
EBITDA Margin (Avg.)
-24.81% lower than 3Y

AI Analysis — Bull vs Bear

6d ago
AI opinion · based on fundamentals
Risk high

AstraZeneca Pharma India has a market cap of about ₹16,450 crore. Its trailing P/E is 97.1 and its price-to-book is 18.87. Sales have grown 31% a year over 3 years and 31% on a TTM basis, but TTM profit has fallen 18%, and the stock has returned -26% over the past year. Return on equity has been steady at 21-23% across 1-, 3-, 5- and 10-year periods, and the company pays out 51.4% of profit as dividends.

Bull Case 7
  • Sales growth has picked up. Revenue grew at a 31% CAGR over 3 years and 31% on a TTM basis, compared with 23% over 5 years and 15% over 10 years.
  • Return on equity has been steady at 23% last year, 23% over 3 years, 22% over 5 years and 21% over 10 years. This suggests the business has kept its profitability through different cycles.
  • The company pays out 51.4% of its profit as dividends, which points to strong cash generation and a shareholder-friendly approach to spending capital.
  • Profit has compounded at 15% over 3 years, 16% over 5 years and 43% over 10 years, even counting the recent TTM decline.
  • The stock has compounded at 21% a year over 10 years and 16% over 5 years, so long-term holders have seen solid returns.
  • The stock is down 26% over the past year, which has pulled its valuation below earlier levels. The P/E is still 97.1, though.
  • The company can draw on its global parent's product pipeline, and 31% sales growth over 3 years suggests new product launches are gaining traction in India.
Bear Case 7
  • The stock trades at a trailing P/E of 97.1. That implies annual earnings of only about ₹169 crore against a ₹16,450 crore market cap, leaving little room for mistakes.
  • Price-to-book is 18.87 (the listed cons cite 18.6), so the stock trades at a steep premium to its book value.
  • TTM profit fell 18% even as sales rose 31%. That gap points to shrinking margins, possibly from product mix, launch costs or pricing pressure.
  • The stock returned -26% over one year, far below its 10-year CAGR of 21%. The market has marked it down over the recent earnings trend.
  • The dividend yield is just 0.55% despite a 51.4% payout, because the valuation is so high. Income investors get little cash return at the current price.
  • Profit grew 15% a year over 3 years, less than half the 31% sales CAGR over the same period. Growth has not been converting well into earnings.
  • With a P/E near 97.1, the valuation assumes growth will keep going for a long time. Profit growth has run at only 15-16% over 3-5 years, which makes the gap between price and earnings a risk.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Headwinds 1
  • ROC fine for filing delay Sep 18

    The Registrar of Companies fined AstraZeneca Pharma India ₹2.38 lakh for filing Form MR-2 late. The form covered Dr. Sanjeev Kumar Panchal's 2023 appointment as Managing Director. The amount is immaterial, but it points to a gap in compliance processes.

Neutral 2
  • Medical Affairs Director resigns Sep 15

    Dr. Sandeep Arora resigned as Director – Medical Affairs, effective September 15, 2026, and the company is looking for a replacement. It is a senior functional role, but there is no sign of wider leadership turnover.

  • Crisil ESG score of 64 Sep 2

    Crisil ESG Ratings gave AstraZeneca Pharma India an ESG score of 64 for FY26. The score uses public data only, and Crisil was not engaged by the company.

TL;DR: The news flow has little effect on the stock, with no updates on earnings, product launches or regulatory approvals. The one negative is a ₹2.38 lakh ROC penalty for a late filing, which costs very little but reflects a governance lapse. A senior medical affairs exit and an unsolicited Crisil ESG score of 64 don't change the investment case. The trend looks stable, and the next real drivers are likely to be quarterly results, new launches from the parent's pipeline and the appointment of Dr. Arora's successor.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
295
311
306
383
388
408
440
480
526
559
612
579
683
Expenses
228
258
291
334
349
355
363
394
445
484
567
518
634
Operating Profit
67
53
15
49
38
53
77
86
81
75
45
61
49
OPM %
23%
17%
4.9%
13%
10%
13%
17%
18%
15%
13%
7%
11%
7%
Other Income
8
25
10
9
-49
8
-26
10
11
1
7
5
9
Interest
0
0
1
0
0
0
0
1
1
1
1
2
2
Depreciation
4
4
4
4
4
9
9
18
17
3
4
6
5
PBT
71
73
20
54
-15
51
42
78
75
73
47
58
51
Tax %
25%
29%
23%
27%
-22%
25%
27%
26%
25%
26%
30%
23%
25%
Net Profit
54
52
16
39
-12
38
31
58
56
54
33
45
38
EPS in Rs
21.54
20.95
6.32
15.79
-4.72
15.37
12.34
23.3
22.33
21.69
13.04
17.95
15.17
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
517
564
544
571
728
832
814
806
1,003
1,296
1,716
2,276
2,432
Expenses
528
547
506
525
657
711
678
719
838
1,111
1,462
2,014
2,202
Operating Profit
-11
16
37
46
71
121
135
86
165
184
254
262
230
OPM %
-2.2%
2.9%
7%
8%
10%
15%
17%
11%
16%
14%
15%
12%
9%
Other Income
6
7
14
12
16
13
13
15
-14
51
-56
23
21
Interest
0
0
0
0
0
1
1
1
1
1
1
4
6
Depreciation
15
17
16
15
15
19
20
17
16
15
40
29
17
PBT
-21
6
36
44
73
114
127
83
134
220
156
252
228
Tax %
0%
9%
44%
41%
25%
37%
27%
26%
26%
26%
26%
26%
—
Net Profit
-21
5
20
26
54
72
93
62
99
162
116
188
170
EPS in Rs
-8.34
2.1
8.02
10.36
21.78
28.88
37.32
24.64
39.72
64.6
46.3
75.01
67.85
Div. Payout %
0%
0%
0%
0%
0%
3%
5%
41%
40%
37%
69%
48%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
146
151
218
242
296
359
451
506
584
707
765
868
Borrowings
0
0
0
0
0
12
12
9
7
5
36
111
Other Liabilities
261
247
193
214
261
330
306
337
389
362
712
1,006
Total Liabilities
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Fixed Assets
101
97
87
75
75
72
81
74
69
67
64
117
CWIP
12
6
5
4
7
24
4
2
1
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
1,454
1,872
Total Assets
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-46
57
38
9
55
87
105
101
58
28
65
-15
Investing
-19
-4
0
-9
4
-171
173
5
18
22
31
19
Financing
0
-1
0
0
0
-6
-9
-9
-24
-44
-66
-92
Net Cash Flow
-64
53
38
-1
59
-90
269
96
52
5
31
-88
Free Cash Flow
-69
48
33
3
37
74
99
94
53
18
64
-18
CFO/OP
393
365
133
28
126
100
101
146
60
46
51
26
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
30
54
29
35
40
37
38
39
39
43
39
34
Inventory Days
157
141
121
229
186
197
198
164
193
140
208
272
Days Payable
203
174
184
257
266
251
221
223
231
121
173
207
Cash Conversion Cycle
-16
21
-34
7
-39
-17
15
-20
1
62
74
99
Working Capital Days
-15
-28
-36
-8
-14
-16
-17
-34
-18
20
22
50
ROCE %
-13%
4%
15%
19%
27%
34%
30%
16%
31%
31%
33%
29%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view AstraZeneca Pharma insights

61 extracted metrics + investor summaries across FY10–FY27.

Log in — free

Shareholding Pattern

Others2.48%Promot.75.00%FIIs2.68%DIIs6.08%Public13.76%As ofJun 2026

Documents

Frequently Asked Questions about AstraZeneca Pharma

What does Astrazeneca Pharma India Ltd do?
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Where is Astrazeneca Pharma India Ltd (ASTRAZEN) listed?
Astrazeneca Pharma India Ltd trades as ASTRAZEN on the NSE and under code 506820 on the BSE.
Which sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a market capitalisation of ₹15,285 Cr, which places it in the Mid Cap band.
What is the PE ratio of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd trades at a PE ratio of 88.89, on earnings per share of ₹52.4, against a book value of ₹349.12 per share.
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
Over the last 52 weeks Astrazeneca Pharma India Ltd has traded between ₹6,120.5 and ₹9,849.5.
Does Astrazeneca Pharma India Ltd pay dividends?
Astrazeneca Pharma India Ltd has a dividend yield of 0.58%.
What is the Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd reported a return on equity of 21.49%. Its debt-to-equity ratio is 0.13.

Company Information

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Website astrazenecaindia.com
CEO Ms. Bhavana Agrawal
Employees 600
Listed 2001-05-04
Face Value ₹ 2
Issued Size 2,50,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTRAZEN.md for Astrazeneca Pharma India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List